{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jia C"],"funding":["Hebei Province Medical Science Research Project Plan"],"pagination":["12765"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11997058"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["Hormone receptor HR-positive/HER2-negative (HR+/HER2-) breast cancer is the most common subtype in China, representing 60-70% of cases, with a rising incidence due to aging demographics and lifestyle changes. CDK4/6 inhibitors such as palbociclib, ribociclib and abemaciclib have been proven effective in treating HR+/HER2 - advanced or metastatic breast cancer (ABC/MBC), though they may increase healthcare costs. This study aims to compare the efficacy, safety and cost-effectiveness of CDK4/6 inhibitors for the second-line treatment of HR+/HER2 - ABC/MBC from the Chinese healthcare perspective. A cohort-based partitioned survival model was utilized, drawing on the survival data published from PALOMA-3, MONALEESA-3 and MONARCH-2 trials. Costs, and quality-adjusted life years (QALYs) were use"],"journal":["Scientific reports"],"pubmed_title":["Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2- advanced or metastatic breast cancer in China."],"pmcid":["PMC11997058"],"funding_grant_id":["20240243"],"pubmed_authors":["Wang M","Li S","Jia C","Shi F","Zhang S","Feng B","Xu H","Wang J"],"additional_accession":[]},"is_claimable":false,"name":"Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2- advanced or metastatic breast cancer in China.","description":"Hormone receptor HR-positive/HER2-negative (HR+/HER2-) breast cancer is the most common subtype in China, representing 60-70% of cases, with a rising incidence due to aging demographics and lifestyle changes. CDK4/6 inhibitors such as palbociclib, ribociclib and abemaciclib have been proven effective in treating HR+/HER2 - advanced or metastatic breast cancer (ABC/MBC), though they may increase healthcare costs. This study aims to compare the efficacy, safety and cost-effectiveness of CDK4/6 inhibitors for the second-line treatment of HR+/HER2 - ABC/MBC from the Chinese healthcare perspective. A cohort-based partitioned survival model was utilized, drawing on the survival data published from PALOMA-3, MONALEESA-3 and MONARCH-2 trials. Costs, and quality-adjusted life years (QALYs) were use","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2025-07-03T03:06:59.947Z","creation":"2025-07-03T03:06:59.947Z"},"accession":"S-EPMC11997058","cross_references":{"pubmed":["40229346"],"doi":["10.1038/s41598-025-97504-3"]}}